A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin

Updated 06/21/2024

Status Recruiting

Clinical Trial Summary

This study aims to evaluate the safety, PK and preliminary anti-tumour activity of SHR-A1912 combined with other therapies in patients with B-cell non-Hodgkin 's lymphoma.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06104553
Study type	Interventional
Source	Shanghai Hengrui Pharmaceutical Co., Ltd.
Contact	Zhenyu Xiao, Medical Director
Phone	021-61053363
Email	zhenyu.xiao.zx7@hengrui.com
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	November 17, 2023
Completion date	June 2026

See also
	Status	Clinical Trial	Phase
	Completed	`NCT00588094` - Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL	Phase 2
	Not yet recruiting	`NCT05091541` - A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma	Phase 1/Phase 2
	Recruiting	`NCT03639181` - Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226)	Phase 2
	Terminated	`NCT01352312` - Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma	Phase 1
	Not yet recruiting	`NCT05771883` - A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide	Phase 1/Phase 2
	Not yet recruiting	`NCT06314828` - A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL	Phase 1
	Enrolling by invitation	`NCT05332054` - Long-Term Follow-up Study
	Suspended	`NCT04697290` - CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients.	Early Phase 1
	Completed	`NCT02564744` - Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL	Phase 2
	Recruiting	`NCT05453669` - Clinical Study of the Efficacy of CD19-CAR-DNT Cells in the Treatment of Relapsed/Refractory B-cell NHL	Phase 1
	Recruiting	`NCT05190068` - HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma	Phase 1
	Suspended	`NCT04746131` - Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)	Phase 1
	Active, not recruiting	`NCT00927797` - Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL)	Phase 2
	Recruiting	`NCT05436223` - Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma	Phase 2
	Completed	`NCT00457782` - A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma	Phase 1
	Not yet recruiting	`NCT03105596` - Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)	Phase 2